These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 17015051

  • 21. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients.
    Djebli N, Rousseau A, Hoizey G, Rerolle JP, Toupance O, Le Meur Y, Marquet P.
    Clin Pharmacokinet; 2006; 45(11):1135-48. PubMed ID: 17048977
    [Abstract] [Full Text] [Related]

  • 22. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
    Roy JN, Barama A, Poirier C, Vinet B, Roger M.
    Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020
    [Abstract] [Full Text] [Related]

  • 23. A Minimal Physiologically-Based Pharmacokinetic Model for Tacrolimus in Living-Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype.
    Itohara K, Yano I, Tsuzuki T, Uesugi M, Nakagawa S, Yonezawa A, Okajima H, Kaido T, Uemoto S, Matsubara K.
    CPT Pharmacometrics Syst Pharmacol; 2019 Aug; 8(8):587-595. PubMed ID: 31087501
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
    Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, Latinne D, Wallemacq P, Mourad M, Haufroid V.
    Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
    [Abstract] [Full Text] [Related]

  • 28. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
    Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE.
    Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
    Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, André JL, Garaix F, Bensman A, Fakhoury M, Jacqz-Aigrain E.
    Clin Pharmacol Ther; 2009 Dec; 86(6):609-18. PubMed ID: 19865079
    [Abstract] [Full Text] [Related]

  • 34. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.
    Ji E, Choi L, Suh KS, Cho JY, Han N, Oh JM.
    Transplantation; 2012 Oct 27; 94(8):866-72. PubMed ID: 22992768
    [Abstract] [Full Text] [Related]

  • 35. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.
    Clin Pharmacol Ther; 2005 Dec 27; 78(6):605-18. PubMed ID: 16338276
    [Abstract] [Full Text] [Related]

  • 36. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.
    Han N, Ha S, Yun HY, Kim MG, Min SI, Ha J, Lee JI, Oh JM, Kim IW.
    Basic Clin Pharmacol Toxicol; 2014 May 27; 114(5):400-6. PubMed ID: 24238261
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation.
    Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE.
    Liver Transpl; 2003 Feb 27; 9(2):130-7. PubMed ID: 12548506
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation.
    Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K.
    Clin Pharmacol Ther; 2001 May 27; 69(5):308-16. PubMed ID: 11371998
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.